Detection of alpha-methylacyl-CoA racemase (AMACR) A biomarker of prostate cancer, in patient blood samples using a nanoparticle electrochemical biosensor

NCUIR > Engineering College > Institute of Materials Science and Engineering > journal & Dissertation > Item 987654321/103447

Please use this identifier to cite or link to this item: https://ir.lib.ncu.edu.tw/handle/987654321/103447

Title:	Detection of alpha-methylacyl-CoA racemase (AMACR) A biomarker of prostate cancer, in patient blood samples using a nanoparticle electrochemical biosensor
Authors:	劉炯權;Lin, Po-Yuan;Cheng, Kai-Lun;McGuffin-Cawley, James D.;Shieu, Fuh-Sheng;Samia, Anna C.;Gupta, Sanjay;Cooney, Matthew;Thompson, Cheryl L.;Liu, Chung Chiun
Contributors:	工學院材料科學與工程研究所
Keywords:	alpha-methylacyl-CoA racemase (AMACR);biosensor;Biosensors;Blood;electrochemical;Electrochemistry;nanoparticles;Prostate cancer
Date:	2012-01-01
Issue Date:	2026-04-23 11:30:40 (UTC+8)
Publisher:	MDPI Multidisciplinary Digital Publishing Institute;Switzerland: MDPI AG
Abstract:	摘要： Although still commonly used in clinical practice to screen and diagnose prostate cancer, there are numerous weaknesses of prostate-specific antigen (PSA) testing, including lack of specificity and the inability to distinguish between aggressive and indolent cancers. A promising prostate cancer biomarker, alpha-methylacyl-CoA racemase (AMACR), has been previously demonstrated to distinguish cancer from healthy and benign prostate cells with high sensitivity and specificity. However, no accurate clinically useful assay has been developed. This study reports the development of a single use, disposable biosensor for AMACR detection. Human blood samples were used to verify its validity, reproducibility and reliability. Plasma samples from 9 healthy males, 10 patients with high grade prostatic intraepithelial neoplasia (HGPIN), and 5 prostate cancer patients were measured for AMACR levels. The average AMACR levels in the prostate cancer patients was 10 fold higher (mean(SD) = 0.077 (0.10)) than either the controls (mean(SD) = 0.005 (0.001)) or HGPIN patients (mean(SD) = 0.004 (0.0005)). At a cutoff of between 0.08 and 0.9, we are able to achieve 100% accuracy in separating prostate cancer patients from controls. Our results provide strong evidence demonstrating that this biosensor can perform as a reliable assay for prostate cancer detection and diagnosis. 其他題名： Biosensors (Basel) 出版者： Switzerland: MDPI AG 出版日期： 2012-09-26 出處： Biosensors (Basel), 2012-09, Vol.2 (4), p.377-387 資源來源： Publicly Available Content Database 版權： Copyright MDPI AG 2012 版權： 2012 by the authors; licensee MDPI, Basel, Switzerland. 2012 識別號： ISSN: 2079-6374 識別號： EISSN: 2079-6374 識別號： DOI: 10.3390/bios2040377 識別號： PMID: 25586028
Appears in Collections:	[Institute of Materials Science and Engineering] journal & Dissertation

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	17	View/Open

社群 sharing

Loading...